The Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry. 

Harvard Business Review looks at whether female board representation could temper overconfidence in male CEOS which often leads to overestimating returns and underestimating risk.

BIO has a foundational belief that diversity is strength, as it provides for multiple viewpoints. The Right Mix Matters campaign seeks to change the look of biopharma boards and leadership.

With a major gap remaining between the demographics of people enrolled in clinical trials and those most likely to use the drugs the FDA approves, the agency issued a draft guidance.

BIO has shifted from being a passive advocate for diversity and inclusion to an active one through its Right Mix Matters initiative.

Dr. Helen Torley explains "Breaking the biopharma glass ceiling isn't just a moral issue; it's a shareholder issue."

Announced on April 16, BIO's Right Mix Matters campaign is aimed at improving gender, racial, ethnic and LGBTQ diversity on the boards of directors, executive suites and functional leadership positions.

Diverse leadership provides more opportunity for innovation and higher performance in financial returns, a Q&A with Helen Torley.

To ensure its member companies are seeing maximum returns BIO created the “Right Mix Matters” campaign.

Despite rules and directives pushing for clinical trials to include proportional representation of both sexes, some researchers and developers are still behind the curve.